Iambic Therapeutics Files for US IPO
Analysis based on 8 articles · First reported Sep 21, 2026 · Last updated Sep 22, 2026
The listing expands the biotech IPO pipeline and signals continued investor appetite for AI-driven drug discovery, supporting valuations across the sector. Underwriting banks and Nasdaq stand to gain fees and listing revenue, while the broader IPO market remains pressured by the Iran war, rising bond yields and rate hikes.
Iambic Therapeutics, a San Diego-based drug developer backed by Nvidia and the Qatar Investment Authority, filed for a US initial public offering on Monday, September 21, 2026, aiming to list on the Nasdaq under the symbol IAM. The company, founded in 2019 as Entos, is advancing a pipeline of AI-discovered drug candidates for solid tumors, with its most advanced candidate IAM1363 in an early-stage trial for solid tumors such as breast cancer. Earlier the same day, Iambic and AbbVie unveiled a multi-year collaboration to accelerate AI-driven discovery of small molecule therapies. Iambic has raised roughly $461.8 million since inception from technology- and healthcare-focused investors, counting Catalio Capital Management, Nexus Ventures and Coatue Management among its major backers. JPMorgan Chase, Jefferies, Bank of America and Citigroup are the underwriters. The filing adds to a busy fall biotech IPO slate that also includes Retension Pharmaceuticals and TRex Bio, which filed on Friday, and ADARx Pharmaceuticals, which launched its roadshow earlier on Monday. Analysts note biotech listings have remained relatively insulated from broader IPO market pressures tied to the Iran war, AI-led disruptions, rising bond yields and interest rate hikes, with all five of the year's best-performing IPOs of $50 million or more being biotechs, according to Renaissance Capital strategist Matt Kennedy.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard